RCS - Diaceutics PLC - Attending 10th Annual HealthTech Investment Forum

DiaceuticsAnnouncement

07/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230907:nRSG4650La&default-theme=true

RNS Number : 4650L  Diaceutics PLC  07 September 2023

 

 

Diaceutics to attend 10(th) Annual HealthTech Investment Forum in Basel on
September 19

 

Belfast and London, 7 September 2023 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical industry, announces that management will
attend and present at the 10 (https://www.sachsforum.com/10htif-about.html)
(th (https://www.sachsforum.com/10htif-about.html) ) Annual HealthTech
Investment Forum (https://www.sachsforum.com/10htif-about.html)  in Basel,
Switzerland on 19 September, 2023. Diaceutics CEO Peter Keeling will be a
speaker at the Revolution in Precision Medicine Panel: Investing in Big Data
& AI.

 

For more information, please click here
(https://www.sachsforum.com/10htif-about.html) .

 

Enquiries:

 Diaceutics PLC                                        Tel: +44 (0)28 9040 6500
 Peter Keeling, Chief Executive Officer               investorrelations@diaceutics.com

 Ryan Keeling, Chief Innovation Officer

 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland

 Kate Hanshaw

 Alma PR                                              Tel: +44 (0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialization solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The Diagnostic
Network®.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFEALIEIIV